Pancreatic Cancer Research

ResearcherColumbia University Irving Medical CenterActive in the last 2 years

Chunhua Xi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6571-9513; OpenAlex author ID A5109509906, A5109556963, A5110670629. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 11

  1. An Insulin-Exosome-TNFAIP8 Axis Drives Stromal Fibrosis and Therapeutic Resistance in Pancreatic Cancer. Co-author DOI 10.1002/advs.202515606↗
  2. [Short-term outcomes of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20230615-000234↗
  3. Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China. Co-author DOI 10.1001/jamanetworkopen.2021.48721↗
  4. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02080-5↗
  5. CA9-Related Acidic Microenvironment Mediates CD8+ T Cell Related Immunosuppression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.832315↗
  6. HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival. Co-author DOI 10.1016/j.canlet.2018.11.007↗
  7. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Co-author DOI 10.1158/1541-7786.mcr-19-0589↗
  8. Inflammation and pancreatic cancer: An updated review. First author DOI 10.4103/sjg.sjg_390_18↗
  9. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase reg… Co-author DOI 10.1186/s12943-017-0619-6↗
  10. The clinical value, regulatory mechanisms, and gene network of the cancer-testis gene STK31 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.16814↗
  11. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. First author DOI 10.18632/oncotarget.11953↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yi Miao · 9 shared papers, 2016–2026 · strength 1.04
  2. Jishu Wei · 7 shared papers, 2016–2024 · strength 0.72
  3. Min Tu · 6 shared papers, 2017–2024 · strength 0.67
  4. Kuirong Jiang · 6 shared papers, 2017–2024 · strength 0.65
  5. Lingdi Yin · 5 shared papers, 2016–2026 · strength 0.64
  6. Zipeng Lu · 5 shared papers, 2017–2022 · strength 0.47
  7. Wentao Gao · 5 shared papers, 2017–2022 · strength 0.47
  8. Kai Zhang · 3 shared papers, 2021–2024 · strength 0.41
  9. Jun Yu · 2 shared papers, 2022–2026 · strength 0.37
  10. Junli Wu · 3 shared papers, 2021–2022 · strength 0.34
  11. Yunpeng Peng · 3 shared papers, 2016–2021 · strength 0.25
  12. Tao Wang · 1 shared paper, 2026 · strength 0.24
  13. Zhenyu Li · 1 shared paper, 2026 · strength 0.24
  14. Qiang Li · 2 shared papers, 2021–2022 · strength 0.23
  15. Kamleshsingh Shadhu · 1 shared paper, 2019 · strength 0.20
  16. Nan Lyu · 1 shared paper, 2024 · strength 0.18
  17. Jiangtao Yin · 1 shared paper, 2024 · strength 0.18
  18. Yang Feng Wu · 1 shared paper, 2024 · strength 0.18
  19. Di Xu · 1 shared paper, 2024 · strength 0.18
  20. Pengfei Wu · 1 shared paper, 2024 · strength 0.18
  21. Gloria Huei-Ting Su · 2 shared papers, 2019 · strength 0.17
  22. Jingjing Zhang · 2 shared papers, 2016–2017 · strength 0.13
  23. Jian‐Min Chen · 1 shared paper, 2022 · strength 0.13
  24. Hao Gao · 1 shared paper, 2022 · strength 0.13
  25. Markus Wolfgang Büchler · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.